A Double-Blind, Placebo Controlled, Single, Escalating Dose Study to Evaluate the Preliminary Pharmacokinetics, Safety and Tolerability of LNK-754 in Healthy Elderly Volunteers
Phase of Trial: Phase I
Latest Information Update: 11 Sep 2009
At a glance
- Drugs OSI 754 (Primary)
- Indications Neurodegenerative disorders
- Focus Pharmacokinetics
- Sponsors Link Medicine Corporation
- 11 Sep 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
- 11 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 27 May 2009 New trial record